Jump to content
Powered by BIOPRO BW
  • BIOPRO BW
  • Healthcare industry
  • Project pages
    • MDR & IVDR
    • Innovation & Startups
Healthcare industry Logo

Main navigation

  • Start page Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close Close
  • Databases

    Databases

    Close Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Press release - 20/06/2023

    CureVac Doses First Patient in Phase 1 Study of Cancer Vaccine Candidate for Surgically Resected Glioblastoma

    CureVac N.V. today announced that it has dosed the first patient with its investigational cancer vaccine CVGBM in a Phase 1 study. CVGBM is based on CureVac’s proprietary second-generation mRNA backbone and features a single mRNA, encoding eight epitopes derived from known tumor-associated antigens with demon­strated relevance in glioblastoma. A first data readout is expected in the second half of 2024.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-doses-first-patient-phase-1-study-cancer-vaccine-candidate-surgically-resected-glioblastoma
  • Dossier - 20/11/2025 A stethoscope and blood pressure monitor

    Prevention as the key to health

    Many serious illnesses can be prevented or at least mitigated through healthy lifestyles and early diagnosis. However, effective prevention requires holistic approaches at all levels of healthcare and the reinforcement of individual health literacy.

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/prevention-key-health
  • FlareOn Biotech - fluorescence-guided tumour margin detection - 01/07/2026 Tisse samples under UV light.

    A sensor designed to visualise residual tumour tissue during surgery

    In order to safely remove tumours in the head and neck region, surgeons must be able to reliably distinguish diseased tissue from healthy tissue. FlareOn Biotech, a start-up based in Frickenhausen, has developed a biochemical sensor capable of visualising tumour cells in tissue samples directly in the operating theatre within just ten minutes. The company is now seeking partners to help bring its diagnostic platform to market.

    https://www.gesundheitsindustrie-bw.de/en/article/news/sensor-designed-visualise-residual-tumour-tissue-during-surgery
  • Press release - 11/05/2026

    What Really Helps People Quit Smoking

    Whether people try to quit smoking depends heavily on public health policies in their respective countries – whether they are successful, however, depends primarily on their personal environment and behavior. This was the finding of researchers from the German Cancer Research Center (DKFZ) in an international study.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/what-really-helps-people-quit-smoking
  • Press release - 05/09/2025

    After EMBL: Umlaut.bio and its potential role in drug development

    Alumnus Bastian Linder discusses the origin of this start-up and how a tRNA mechanism is helping scientists understand the importance and use of various RNA modifications as they pertain to disease.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/after-embl-umlautbio-and-its-potential-role-drug-development
  • Press release - 29/11/2023

    Tracing the Evolution of the Cerebellum

    Heidelberg scientists unveil genetic programmes controlling the development of cellular diversity in the cerebellum of humans and other mammals. The research results have now been published in the journal Nature.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/tracing-evolution-cerebellum
  • Press release - 19/05/2025

    How the Epstein-Barr virus promotes its spread in the body

    Many people are infected with the Epstein-Barr virus (EBV), and most are unaware of it. However, EBV can sometimes cause cancer, and this pathogen also appears to play an important role in multiple sclerosis and other autoimmune diseases. Researchers have discovered that EBV increases the ability of infected immune cells to migrate. In this way, the pathogen promotes its spread in the body – a discovery that may have therapeutic implications.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-epstein-barr-virus-promotes-its-spread-body
  • Rewriting the transcript to heal diseases - 29/01/2026 A colourful mRNA to which an arginyl tRNA docks. Both nucleic acid sequences are modified at one point.

    Therapy involving the umlauts of the genetic alphabet

    tRNAs are essential components of the protein synthesis machinery that also act as molecular switches in gene regulation and consequently in disease processes such as cancer. The Heidelberg-based start-up Umlaut.bio is developing novel therapeutics that specifically target tRNAs to intervene at the molecular origin of disease.

    https://www.gesundheitsindustrie-bw.de/en/article/news/therapy-involving-umlauts-genetic-alphabet
  • Press release - 21/05/2025

    How aging changes the blood system in humans and mice

    The reservoir of blood stem cells shrinks with age. It becomes increasingly dominated by stem cells that produce immune cells associated with chronic inflammation. Almost all of the 60-year-olds studied show this change. The new discovery could help explain the chronic inflammation that occurs with age and makes us more susceptible to disease. It could also help identify early warning signs of unhealthy aging processes.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-aging-changes-blood-system-humans-and-mice
  • Press release - 14/03/2024

    Planned NMI spin-off: immuneAdvice successful in start-up competition

    Does our therapeutic approach work against cancer? The answer to this question can make the difference between life and death - and is still difficult to answer. A team from the NMI Natural and Medical Sciences Institute at the University of Tübingen and the Werner Siemens Imaging Center Tübingen has developed a technique for observing immune cells.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/geplante-nmi-ausgruendung-immuneadvice-bei-startup-wettbewerb-erfolgreich
  • Press release - 05/11/2024

    How biomedical innovation improves preclinical research

    3D tumor models, simulations of drug responses or plant stems used for testing heart stents: the 3R-BioMedicUS center at the University of Stuttgart is developing innovative biomedical approaches to improve preclinical studies, to be seen in the new video.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-biomedical-innovation-improves-preclinical-research
  • Press release - 17/01/2024

    Immatics Announces Pricing of $175 Million Public Offering

    Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, announced today the pricing of an underwritten public offering of 15,925,000 ordinary shares at a public offering price of $11.00 per share.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/immatics-announces-pricing-175-dollar-million-public-offering
  • Press release - 13/03/2023

    AI and multispectral imaging facilitate keyhole surgery

    How can camera images be used during minimally invasive surgeries to assess whether the operated organ is sufficiently perfused with blood? Scientists from the German Cancer Research Center (DKFZ) and the Städtisches Klinikum Karlsruhe have now succeeded in automatic monitoring of ischemia during a kidney surgery using only the optical properties of the tissue and not relying on injection of contrast agent.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/ki-und-moderne-bildgebung-erleichtern-schluesselloch-chirurgie
  • Press release - 16/09/2021

    Organ twin: a “flight simulator” for surgeons

    Cyber Valley researchers have created medical educational tools that could potentially train the surgeons of the future, much like flight simulators train pilots. The team developed a range of artificial organ phantoms to serve as training platforms for surgeons. Thanks to the structured data of experienced medical professionals, a quantitative and objective assessment of a trainee’s skills can be assessed in real time.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/organ-twin-flight-simulator-surgeons
  • Press release - 06/03/2025

    NMI TT in Reutlingen and Düsseldorf University Women's Hospital develop high-precision method for analyzing individual circulating tumor cells

    Researchers have developed a new method that enables a more precise analysis of individual tumor cells circulating in the blood. This allows not only the previously possible genomic investigation of such tumor cells, but also the focused analysis of single-cell signaling pathways at the functional protein level. The combined analysis of the mutated genome and signaling proteins opens up new avenues for more targeted treatment methods.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/nmi-tt-reutlingen-and-duesseldorf-university-womens-hospital-develop-high-precision-method-analyzing-individual-circulating-tumo
  • Press release - 19/03/2025

    Pocket-sized breath test for stomach bacteria Mini sensor analyses breath for infection with Helicobacter pylori

    Stomach ulcers, gastritis and even stomach cancer are often the result of an infection with Helicobacter pylori. If the bacterium remains unrecognised for a long time, this can have serious consequences. Researchers have now developed a miniaturisable sensor system for the mobile analysis of breath that is effective, fast and inexpensive. The research team uses a biological survival trick of the stomach germ to detect the bacterium.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/pocket-sized-breath-test-stomach-bacteria-mini-sensor-analyses-breath-infection-helicobacter-pylori
  • Press release - 22/03/2024

    New Emmy Noether junior research group for biological data science

    An Emmy Noether junior research group at Heidelberg University is investigating how to gain new insights into fundamental biological mechanisms from large-scale molecular data sets. Led by Junior Professor Dr Britta Velten, it has started work at the Centre for Organismal Studies and the Interdisciplinary Center for Scientific Computing.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-emmy-noether-junior-research-group-biological-data-science
  • Press release - 27/03/2024

    Heidelberg Pharma granted orphan drug designation by FDA for its proprietary ATAC candidate HDP-101

    Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), is pleased to announce that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for the treatment of multiple myeloma to its lead candidate HDP-101. Heidelberg Pharma is investigating the candidate in a clinical Phase I/IIa study for the treatment of relapsed/refractory multiple myeloma (RRMM).

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/heidelberg-pharma-granted-orphan-drug-designation-fda-its-proprietary-atac-candidate-hdp-101
  • The Baden-Württemberg healthcare industry

    The biotechnology sector

    Baden-Württemberg is currently home to 193 biotechnology companies, most of which specialise in so-called ‘red biotechnology’ - i.e. applications in the medical and pharmaceutical sectors. The biotech sector includes not only traditional biotechnology companies, but also companies from the fields of bioinformatics, diagnostics, analytics and biotechnological production.

    https://www.gesundheitsindustrie-bw.de/en/location/biotech
  • Press release - 26/05/2026

    How blood stem cells diversify

    Different types of bone marrow stem cells give rise to blood and immune cells. A team led by Simon Haas now reports in ​“Nature Cell Biology” how that diversity develops. The findings could help improve stem cell therapies, including treatments for blood cancers.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-blood-stem-cells-diversify
  • Press release - 18/01/2021

    How a protein variant could explain resistance to sleeping sickness drug

    A specific variant of the surface protein VSG of African trypanosomes, the causative agents of sleeping sickness, is associated with resistance to the important drug Suramin. Scientists at the German Cancer Research Center have now been able to find a possible explanation for the formation of resistance based on the crystal structure of this protein variant.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-protein-variant-could-explain-resistance-sleeping-sickness-drug
  • Press release - 24/05/2024

    Research Training Group on Cancer Surgery: German Research Foundation approves second funding period

    Since 2019, the Research Training Group (RTG) "Intraoperative Multisensoric Tissue Differentiation in Oncology," a collaboration between the University of Stuttgart and the University of Tübingen, has been advancing research in medical technology. With the help of new sensor methods, the researchers want to help make surgical procedures on cancer patients safer and more effective.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/research-training-group-cancer-surgery-german-research-foundation-approves-second-funding-period
  • Dossier - 09/02/2015 The photo shows the hands of a scientist rotating a flask with a red liquid.

    Chemical tools for biological applications

    The boundaries between traditional scientific disciplines are becoming less and less distinct. Interdisciplinary cooperation is often required to study complex processes and biomolecular issues. Interdisciplinary cooperation is central to chemical biology.

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/chemical-tools-for-biological-applications
  • Dossier - 09/09/2013 Immunofluorescence image of two dendritic mouse cells with MHC complexes (labelled with red-fluorescent antibodies) on their surface.

    New trends in the field of immunology

    B- and T- lymphocytes along with macrophages have long been regarded as the most important cells of the human immune system and have been a major focus of research. This has now changed and it is now the dendritic cells that are regarded as the major components of the adaptive immune system. Research into innate immune defence mechanisms has become more important due to the discovery of the role of Toll-like receptors as first-line of defence.

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/new-trends-in-the-field-of-immunology
  • Press release - 13/12/2024

    Schizophrenia: NMI observes processes in nerve cells

    Up to now, schizophrenia has mainly been treated symptomatically, as little is known about the exact underlying processes. Researchers at the NMI Natural and Medical Sciences Institute in Reutlingen have succeeded in gaining a better understanding of the driving mechanisms of the disease. This offers opportunities for the development of new drugs. They have published their findings in the journal BMC Psychiatry.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/schizophrenia-nmi-observes-processes-nerve-cells

Page 12 / 17

sb_search.block.search_result.other.pages

  • eine Seite vor
  • 1
  • …
  • 10
  • 11
  • 12
  • 13
  • 14
  • …
  • 17
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • MDR & IVDR
    • Innovation & Startups
  • Portals
    • BIOPRO BW
    • Healthcare industry
  • To top

stay informed

Newsletter abonnieren

Social Media

  • Xing Xing
  • Twitter visit Twitter
  • LinkedIn visit LinkedIn
  • Rss visit RSS
  • Privacy statement
  • Accessability Declaration
  • Legal notice
  • Sitemap
  • Contact
© 2026
Website address: https://www.gesundheitsindustrie-bw.de/en/search